BioArctic AB (publ) (STO:BIOA.B)
300.60
-5.60 (-1.83%)
Nov 20, 2026, 5:29 PM CET
BioArctic AB Revenue
BioArctic AB had revenue of 247.53M SEK in the quarter ending June 30, 2026, a decrease of -36.88%. This brings the company's total for the last twelve months to 1.00B, down -46.09% year-over-year. In the year 2025, BioArctic AB had annual revenue of 2.00B with 676.80% growth. That makes BioArctic AB the 22,866th largest company in the world by revenue and 289th in Sweden.
Revenue (ttm)
1.00B
Revenue Growth
-46.09%
P/S Ratio
26.60
Revenue / Employee
6.68M
Employees
150
Market Cap
26.67B
Revenue by Geography
- North America 1.32B 66.3%
- Asia 593.78M 29.7%
- Europe 80.15M 4.0%
- Others 270.00K 0.0%
Fiscal year ended Dec 31, 2025 See the full BioArctic AB breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.00B | 1.74B | 676.80% |
| Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
| Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
| Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
| Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Camurus AB | 2.42B |
| Saniona AB | 424.56M |
| Hansa Biopharma AB | 301.64M |
| Genovis AB (publ.) | 145.23M |
| Egetis Therapeutics AB | 70.00M |
| Medivir AB | 8.51M |
| Vicore Pharma Holding AB | 3.83M |
| Flerie AB | 2.60M |
BioArctic AB News
- 4 days ago - New three-year real-world data on Leqembi® presented at CTAD 2026 - PRNewsWire
- 4 days ago - Invitation to presentation of BioArctic's third quarter report for July - September 2026 on November 25 at 9:30 a.m. CET - PRNewsWire
- 5 days ago - Eisai Report Five-Year Leqembi Data Showing Sustained Alzheimer's Benefit - Nasdaq
- 5 days ago - Five-year data of continuous Leqembi® treatment show increasing benefit over time - PRNewsWire
- 9 days ago - BioArctic Partner Eisai Launches Leqembi Pen In Japan For Early Alzheimer's Disease - Nasdaq
- 9 days ago - Leqembi® Pen subcutaneous treatment launched in Japan - PRNewsWire
- 19 days ago - BioArtic's BrainTransporter Collaboration With Novartis Ends Following Program Discontinuation - Nasdaq
- 19 days ago - BioArctic collaborator Novartis terminates agreement - PRNewsWire